Header Logo

Connection

HANA EL SAHLY to RNA, Messenger

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about RNA, Messenger.
HANA EL SAHLY
Connection Strength
0.313
RNA, Messenger
  1. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J Infect Dis. 2022 11 11; 226(10):1731-1742.
    View in: PubMed
    Score: 0.128
  2. Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review. Transl Res. 2022 04; 242:1-19.
    View in: PubMed
    Score: 0.120
  3. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J Infect Dis. 2023 Dec; 137:28-39.
    View in: PubMed
    Score: 0.034
  4. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.